Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function

Transplantation

Volumn 66, Issue 8, 1998, Pages 1104-1107

  Pescovitz, Mark D ^a   Pruett, Timothy L ^b   Gonwa, Thomas ^c   Brook, Bonnie ^a   McGory, R ^b   Wicker, K ^c   Griffy, Kay ^d   Robinson, Charles A ^d   Jung, Donald ^d  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Roche Global Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIALYSIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALGORITHMS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GANCICLOVIR; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS;

EID: 0032573205     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199810270-00023     Document Type: Article

References (17)

1. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
2. McCarthy JM, Karim MA, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993; 55: 1277.
3. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
4. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721.
5. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995; 123: 18.
6. Goodrich GM, Mon M, Gleaves CA, Du Mond C, Cays M, Ebeling DF. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601.
7. Merigan TC, Renlund DG, Keay S, Bristow MR, Stames V, O'Connell JB. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
8. Drew WL, Ives D, Lalezari J, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615.
9. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995; 171: 1431.
10. Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17: 425.
11. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagnost Virol 1993; 1: 179.
12. Plotkin SA, Drew WA, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,2-dihydroxy-2-propoxymethyl)guanine. J Infect Dis 1985; 152: 833.
13. Gane E, Saliba F, Valdecasas G, et al. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: results of a multicenter, multinational clinical trial. Lancet 1997; 350: 1729.
14. Page T, Sherwood C, Connor JD, Tarnowski T. Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. J Chromatogr B Biomed Appl 1996; 675: 342.
15. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491.
16. Rosen HR, Benner KG, Flora KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63: 476.
17. Brown F, Arum I, Francis G, Patel M, Malcolm S. Ganciclovir prodrug (RS-79070)-multiple dose, dose-ranging study with effect of food. Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997: 209.